soul trial oral semaglutide cardiovascular outcomes 2025 PDF) and in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the Randomized Forecasting Trial Milestones: A Predictive

FDA Enforcement Actions and Safety Concerns In September 2025, the FDA issued over 50 warning letters to compounders marketing GLP-1 products as generic equivalents to FDA-approved drugs

Cardiovascular Imaging 201920636643

Whether someone uses medication or not, the foundations still matter: protein, fiber, movement, sleep, stress management, gut health, and blood sugar stability

Can triple agonism outperform incretin therapy

How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test may help provide context on your individual predispositions in key GLP-1 signaling and metabolic pathways

Cognitive performance at baseline At baseline, performance in numerous cognitive tasks were impaired